Comparison of cycloplegic and mydriatic effect between cyclopentolate, tropicamide, and combination in children: a narrative review
Main Article Content
Keywords
cyclopentolate, tropicamide, cycloplegia, mydriasis, cycloplegic, pupillary dilation
Abstract
Introduction: Cycloplegic refraction is essential in pediatric eye examination. Inadequate cycloplegia provides inaccurate refraction so that therapeutic approaches become inappropriate. The ideal cycloplegic agent should have a rapid onset of action, quick recovery, adequate cycloplegia, without local or systemic side effects. None of the currently available drugs fulfil all of these criteria. To compare the cycloplegic and mydriatic effect of cyclopentolate, tropicamide, and their combination in children.
Methods: A comprehensive literature search was performed in PubMed, ScienceDirect, and Cochrane Library by entering keywords: “cyclopentolate”, “tropicamide”, “cycloplegia”, “cycloplegic”, “mydriasis”, and “pupillary dilation”. The search was limited to articles in English and published between January 2000 and November 2019. The findings from the related articles were presented as narrative reviews.
Result: Twelve articles were eligible to the review process. Four articles were conduct in subjects with dark irides. The cycloplegic agents used were tropicamide, cyclopentolate, and their combination, with or without phenylephrine.
Conclusion: Cyclopentolate, tropicamide, and their combination is widely used to achieve maximum cycloplegia. Several factors, such as age, iris color, and refractive status, need to be considered in the selection of dose, concentration, and regimen(s) of cycloplegic agents.
References
2. Kyei S, Nketsiah AA, Asiedu K, Awuah A, Owusu-Ansah A. Onset and duration of cycloplegic action of 1% cyclopentolate – 1% tropicamide combination. Afr Health Sci. 2017;17(3):923-932. doi:10.4314/ahs.v17i3.36
3. Laojaroenwanit S, Layanun V, Praneeprachachon P, Pukrushpan P. Time of maximum cycloplegia after instillation of cyclopentolate 1% in children with brown irises. Clin Ophthalmol. 2016;10:897-902. doi:10.2147/OPTH.S102611
4. Yazdani N, Sadeghi R, Momeni-Moghaddam H, Zarifmahmoudi L, Ehsaei A. Comparison of cyclopentolate versus tropicamide cycloplegia: A systematic review and meta-analysis. J Optom. 2018;11:135-143. doi:10.1016/j.optom.2017.09.001
5. Fan DSP, Rao SK, Ng JSK, Yu CBO, Lam DSC. Comparative study on the safety and efficacy of different cycloplegic agents in children with darkly pigmented irides. Clin Exp Ophthalmol. 2004;32:462-467. doi:10.1111/j.1442-9071.2004.00863.x
6. Yoo SG, Cho MJ, Kim US, Baek S-H. Cycloplegic refraction in hyperopic children: Effectiveness of a 0.5% tropicamide and 0.5% phenylephrine addition to 1% cyclopentolate regimen. Korean J Ophthalmol. 2017;31(3):249. doi:10.3341/kjo.2016.0007
7. Sani RY, Hassan S, Habib SG, Ifeanyichukwu EP. Cycloplegic effect of atropine compared with cyclopentolate-tropicamide combination in children with hypermetropia. Niger Med J 2016;57: 173-177. doi:10.4103/0300-1652.184065
8. Pi LH, Zhao JL, Liu Q, et al. Comparison of cycloplegic retinoscopy using cyclopentolate or tropicamide eye drops in an epidemiologic study of pediatric refraction among 1907 school-aged children. Sci Res Essays. 2011;6(3):635-640. doi:10.5897/SRE10.1018
9. Chng O, Jones N, Kian KB, Ming KH, Kee S. Is tropicamide a more effective cycloplegic than cyclopentolate in children with dark irides? Australian Orthoptic Journal, 2005; 38:2-4.
10. Egashira SM, Kish LL, Twelker JD, Mutti DO, Zadnik K, Adams AJ. Comparison of cyclopentolate versus tropicamide cycloplegia in children. Optom Vis Sci. 1993; 70:1019-1026. doi:10.1097/00006324-199312000-00005
11. Gupra SK. Mydriatics and Cycloplegics. In: Gupra SK, Agarwal R, Srivastava S, eds. Textbook on Clinical Ocular Pharmacology and Therapeutics. New Delhi, India: Jaypee Brothers Medical Publishers; 2014:87-95. doi:10.5005/jp/books/12384
12. Minderhout HM, Joosse M V, Grootendorst DC, Schalij-Delfos NE. A randomized clinical trial using atropine, cyclopentolate, and tropicamide to compare refractive outcome in hypermetropic children with a dark iris; skin pigmentation and crying as significant factors for hypermetropic outcome. Strabismus. 2019;27(3):127-138. doi:10.1080/09273972.2019.1629466
13. Bagheri A, Givrad S, Yazdani S, Mohebbi MR. Optimal dosage of cyclopentolate 1% for complete cycloplegia: A randomized clinical trial. Eur J Ophthalmol. 2007;17(3):294-300. doi:10.1177/112067210701700303
14. Ebri A, Kuper H, Wedner S. Cost-effectiveness of cycloplegic agents: Results of a randomized controlled trial in Nigerian children. Invest Ophthalmol Vis Sci. 2007; 48:1025-1031. doi: 10.1167/iovs.06-0604
15. Park JH, Lee YC, Lee SY. The comparison of mydriatic effect between two drugs of different mechanism. Korean J Ophthalmol. 2009;23(1):40-42. doi:10.3341/kjo.2009.23.1.40
16. Anderson HA, Bertrand KC, Manny RE, Hu YS, Fern KD. A Comparison of two drug combinations for dilating dark irides. Optom Vis Sci. 2010;87(2):120-124. doi:10.1097/OPX.0b013e3181cc8da3
17. Sedhu PA, Pushpakaran A, Kurian C. Effect on ciliary muscles and accommodation: Comparative study between topical tropicamide 1% versus combination of tropicamide 0.8% and phenylephrine 5%. Int J Med Res Prof 2017; 3(5):323-327. doi:10.21276/ijmrp
18. Ihekaire DE. The comparative efficacy of cyclopegic drugs–tropicamide and cyclopentolate on school children. International Journal of Scientific Research in Education. 2012; 5(3):223-246.
19. Patel AJ, Simon JW, Hodgetts DJ. Cycloplegic and mydriatic agents for routine ophthalmologic examination: A survey of pediatric ophthalmologists. J AAPOS. 2004;8:274-277. doi:10.1016/j.jaapos.2004.01.004
20. Siderov J, Nurse S. The mydriatic effect of multiple doses of tropicamide. Optom Vis Sci 2005; 82:955–958. doi:10.1097/01.opx.0000187847.48093.55
21. Kleinstein RN, Mutti DO, Manny RE et al. Cycloplegia in African-American children. Optom Vis Sci 1999; 76:102-107.